JP2025508896A5 - - Google Patents
Info
- Publication number
- JP2025508896A5 JP2025508896A5 JP2024550789A JP2024550789A JP2025508896A5 JP 2025508896 A5 JP2025508896 A5 JP 2025508896A5 JP 2024550789 A JP2024550789 A JP 2024550789A JP 2024550789 A JP2024550789 A JP 2024550789A JP 2025508896 A5 JP2025508896 A5 JP 2025508896A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ctps1
- bcl2
- pharmaceutically acceptable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305225.9 | 2022-03-01 | ||
| EP22305225 | 2022-03-01 | ||
| EP22306429.6 | 2022-09-27 | ||
| EP22306429 | 2022-09-27 | ||
| PCT/EP2023/055217 WO2023166076A1 (en) | 2022-03-01 | 2023-03-01 | Combinations of ctps1 and bcl2 inhibitors for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508896A JP2025508896A (ja) | 2025-04-10 |
| JP2025508896A5 true JP2025508896A5 (https=) | 2026-03-09 |
Family
ID=85384465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550789A Pending JP2025508896A (ja) | 2022-03-01 | 2023-03-01 | 癌のためのｃｔｐｓ１阻害剤とｂｃｌ２阻害剤の組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250177394A1 (https=) |
| EP (1) | EP4486347A1 (https=) |
| JP (1) | JP2025508896A (https=) |
| AU (1) | AU2023228045A1 (https=) |
| CA (1) | CA3244038A1 (https=) |
| WO (1) | WO2023166076A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019106156A1 (en) | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
| IL288508B2 (en) | 2019-06-04 | 2026-02-01 | Step Pharma S A S | History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases |
| WO2024133730A1 (en) * | 2022-12-21 | 2024-06-27 | Step Pharma S.A.S. | Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3717465B1 (en) | 2017-11-30 | 2026-01-21 | Step Pharma S.A.S. | Compounds |
| WO2019106156A1 (en) | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
| MX2020009887A (es) | 2018-03-23 | 2020-10-12 | Step Pharma S A S | Derivados de aminopiridina como inhibidores de ctps1. |
| BR112021005986A2 (pt) | 2018-10-23 | 2021-06-29 | Step Pharma S.A.S. | derivados de aminopirimidina como inibidores de ctps1 |
| IL288508B2 (en) | 2019-06-04 | 2026-02-01 | Step Pharma S A S | History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases |
| EP3980410B1 (en) | 2019-06-04 | 2025-02-19 | Step Pharma S.A.S. | N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases |
| EP4041715A1 (en) | 2019-09-20 | 2022-08-17 | Step Pharma S.A.S. | Sulfonamide inhibitors as ctps 1 inhibitors |
| WO2021053402A2 (en) | 2019-09-20 | 2021-03-25 | Step Pharma S.A.S. | Compounds |
| US12331046B2 (en) | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
-
2023
- 2023-03-01 WO PCT/EP2023/055217 patent/WO2023166076A1/en not_active Ceased
- 2023-03-01 US US18/842,972 patent/US20250177394A1/en active Pending
- 2023-03-01 AU AU2023228045A patent/AU2023228045A1/en active Pending
- 2023-03-01 EP EP23707748.2A patent/EP4486347A1/en active Pending
- 2023-03-01 JP JP2024550789A patent/JP2025508896A/ja active Pending
- 2023-03-01 CA CA3244038A patent/CA3244038A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508896A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JP2010538076A5 (https=) | ||
| JP2023529908A5 (https=) | ||
| JP2007504160A5 (https=) | ||
| JP2017525757A5 (https=) | ||
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| JP2024545233A5 (https=) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2015510886A5 (https=) | ||
| JP2008520742A5 (https=) | ||
| RU2011134634A (ru) | Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| RU2008112184A (ru) | Производное тиазола | |
| DE60118590D1 (de) | Medizinische zusammensetzungen als begleittherapie gegen krebs | |
| KR960010000A (ko) | 종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물 | |
| JP2008528467A5 (https=) | ||
| JP2012530765A5 (https=) | ||
| JP2011506402A5 (https=) | ||
| JP2020517595A (ja) | サイクリン依存性キナーゼｃｄｋ９の新規阻害剤 | |
| JP2006509015A5 (https=) | ||
| CA2431952A1 (en) | Muscarinic antagonists | |
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов | |
| JP2005511545A5 (https=) | ||
| NO20033584D0 (no) | Bredspektrede 2-(substituert-amino)-benzotiazolsulfonamid-hiv- proteaseinhibitorer | |
| JP2017534569A5 (https=) |